News Releases

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H. C.

On-track to complete BLA submission in the US in the fourth quarter of 2020 Entered into a license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China with $12M upfront payment Manufacturing of PPQ campaign drug substance batches has been

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2020-- August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity

Sesen to receive $12 million upfront and $23 million in potential regulatory and tech transfer milestone payments Sesen eligible to receive royalties on net sales in China Sesen to host conference call Friday, July 31 st at 8:00 a.m. EDT CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare

Manufacturing and release testing of the Fujifilm pre-PPQ batch completed successfully Positive Interactions with EMA on Regulatory Pathway for Vicinium ® in Europe Market research conducted in 1Q 2020 supports Urologists prefer Vicinium to Keytruda ® CAMBRIDGE, Mass.

No additional clinical trials were requested by the CHMP for submission of Vicinium marketing authorization application Anticipated submission of marketing authorization application in early 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 11,

Company on track to complete Vicinium ® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted